These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 30808623)
1. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Poppelaars PBM; van Tuyl LHD; Boers M Ann Rheum Dis; 2019 May; 78(5):586-589. PubMed ID: 30808623 [TBL] [Abstract][Full Text] [Related]
2. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Landewé RB; Boers M; Verhoeven AC; Westhovens R; van de Laar MA; Markusse HM; van Denderen JC; Westedt ML; Peeters AJ; Dijkmans BA; Jacobs P; Boonen A; van der Heijde DM; van der Linden S Arthritis Rheum; 2002 Feb; 46(2):347-56. PubMed ID: 11840436 [TBL] [Abstract][Full Text] [Related]
3. Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Konijn NPC; van Tuyl LHD; Boers M; den Uyl D; Ter Wee MM; van der Wijden LKM; Bultink IEM; Kerstens PJSM; Voskuyl AE; van Schaardenburg D; Nurmohamed MT; Lems WF Rheumatology (Oxford); 2017 Sep; 56(9):1586-1596. PubMed ID: 28859326 [TBL] [Abstract][Full Text] [Related]
4. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488 [TBL] [Abstract][Full Text] [Related]
5. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. van Tuyl LH; Boers M; Lems WF; Landewé RB; Han H; van der Linden S; van de Laar M; Westhovens R; van Denderen JC; Westedt ML; Peeters AJ; Jacobs P; Huizinga TW; van de Brink H; Dijkmans BA; Voskuyl AE Ann Rheum Dis; 2010 May; 69(5):807-12. PubMed ID: 19451137 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA. Stouten V; Westhovens R; Pazmino S; De Cock D; Van der Elst K; Joly J; Verschueren P; Rheumatology (Oxford); 2019 Dec; 58(12):2284-2294. PubMed ID: 31236568 [TBL] [Abstract][Full Text] [Related]
7. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Boers M; Verhoeven AC; Markusse HM; van de Laar MA; Westhovens R; van Denderen JC; van Zeben D; Dijkmans BA; Peeters AJ; Jacobs P; van den Brink HR; Schouten HJ; van der Heijde DM; Boonen A; van der Linden S Lancet; 1997 Aug; 350(9074):309-18. PubMed ID: 9251634 [TBL] [Abstract][Full Text] [Related]
8. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. ter Wee MM; den Uyl D; Boers M; Kerstens P; Nurmohamed M; van Schaardenburg D; Voskuyl AE; Lems WF Ann Rheum Dis; 2015 Jun; 74(6):1233-40. PubMed ID: 24818633 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. Boers M; van Tuyl L; van den Broek M; Kostense PJ; Allaart CF Ann Rheum Dis; 2013 Mar; 72(3):406-9. PubMed ID: 23155223 [TBL] [Abstract][Full Text] [Related]
10. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795 [TBL] [Abstract][Full Text] [Related]
11. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408 [TBL] [Abstract][Full Text] [Related]
12. [Combination therapy in early rheumatoid arthritis: the COBRA study]. Boers M; Verhoeven AC; van der Linden S Ned Tijdschr Geneeskd; 1997 Dec; 141(50):2428-32. PubMed ID: 9555126 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis. Verhoeven AC; Bibo JC; Boers M; Engel GL; van der Linden S Br J Rheumatol; 1998 Oct; 37(10):1102-9. PubMed ID: 9825750 [TBL] [Abstract][Full Text] [Related]
15. Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis. Rasch LA; van Tuyl LH; Lems WF; Boers M Neuroimmunomodulation; 2015; 22(1-2):51-6. PubMed ID: 25227967 [TBL] [Abstract][Full Text] [Related]
16. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Verschueren P; Esselens G; Westhovens R Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681 [TBL] [Abstract][Full Text] [Related]
17. The COBRA trial 20 years later. Boers M Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S46-51. PubMed ID: 22018183 [TBL] [Abstract][Full Text] [Related]
18. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599 [TBL] [Abstract][Full Text] [Related]
19. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Seegobin SD; Ma MH; Dahanayake C; Cope AP; Scott DL; Lewis CM; Scott IC Arthritis Res Ther; 2014 Jan; 16(1):R13. PubMed ID: 24433430 [TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]